208 related articles for article (PubMed ID: 11365186)
1. Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients.
Gallant JE; Block DS
J Int Assoc Physicians AIDS Care; 1998 May; 4(5):32-5. PubMed ID: 11365186
[TBL] [Abstract][Full Text] [Related]
2. Daily dosing of highly active antiretroviral therapy.
Rosenbach KA; Allison R; Nadler JP
Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
[TBL] [Abstract][Full Text] [Related]
3. Impact of once- and twice-daily dosing regimens on adherence and overall safety.
Hawkins T
AIDS Read; 2004 Jun; 14(6):320-2, 324, 329-31, 334-6. PubMed ID: 15243968
[TBL] [Abstract][Full Text] [Related]
4. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
[TBL] [Abstract][Full Text] [Related]
7. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Arici C; Ravasio L; Suter F
Antivir Ther; 2003 Aug; 8(4):339-46. PubMed ID: 14518703
[TBL] [Abstract][Full Text] [Related]
8. Simplifying antiretroviral therapy.
Tapper ML; Flexner C; Eron JJ; Molina JM
AIDS Read; 2004 Jul; 14(7):355-60, 367-71. PubMed ID: 15282865
[TBL] [Abstract][Full Text] [Related]
9. Making the most of once-daily anti-HIV therapy.
Cox S
Posit Aware; 1998; 9(6):43. PubMed ID: 11366482
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence in patients with HIV infection: a comparison of two measurement methods.
Melbourne KM; Geletko SM; Brown SL; Willey-Lessne C; Chase S; Fisher A
AIDS Read; 1999 Aug; 9(5):329-38. PubMed ID: 12737122
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
[TBL] [Abstract][Full Text] [Related]
12. Initiatives to promote adherence in HIV-infected patients.
Reynolds NR
AIDS Read; 1999; 9(1):53-6. PubMed ID: 12728885
[TBL] [Abstract][Full Text] [Related]
13. Adherence to HAART.
Proj Inf Perspect; 1997 Jul; (22):20-3. PubMed ID: 11364576
[TBL] [Abstract][Full Text] [Related]
14. Survey: patients not complying with regimens.
AIDS Alert; 1998 Jul; 13(7):77-8. PubMed ID: 11365587
[TBL] [Abstract][Full Text] [Related]
15. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M; Koffi CK
AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
[TBL] [Abstract][Full Text] [Related]
16. Adherence, compliance, and HAART.
Williams A; Friedland G
AIDS Clin Care; 1997 Jul; 9(7):51-4, 58. PubMed ID: 11364415
[TBL] [Abstract][Full Text] [Related]
17. Drug Guide 2000: the antiretroviral agents.
Gallant JE
Posit Aware; 2000; 11(1):30-1. PubMed ID: 11366347
[TBL] [Abstract][Full Text] [Related]
18. Strategies for improving patient adherence to therapy and long-term patient outcomes.
Battaglioli-DeNero AM
J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S17-22. PubMed ID: 17275718
[TBL] [Abstract][Full Text] [Related]
19. HAART with didanosine once versus twice daily: adherence and efficacy.
Roca B; Lapuebla C; Vidal-Tegedor B
Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
[TBL] [Abstract][Full Text] [Related]
20. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B;
Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
